Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, Sabina A Murphy, Xinhui Ran, Candace R Bramson, Madelyn Curto, Vesper Ramos, Alexandra Jevne, Julia F Kuder, Subodh Verma, Wojtek Wojakowski, Steven G Terra, Marc S Sabatine, Brian A Bergmark, Nicholas A Marston
AIMS: Remnant cholesterol and very low-density lipoprotein cholesterol (VLDL-C) are increasingly recognized risk factors for atherosclerotic disease with few therapeutic options. Angiopoietin-like 3 (ANGPTL3), a key protein in the metabolism of triglyceride-rich lipoproteins, is a promising target. METHODS AND RESULTS: TRANSLATE-TIMI 70 was a double-blind, placebo-controlled randomized trial testing seven dose regimens of vupanorsen, an antisense oligonucleotide against ANGPTL3, in adults with non-HDL-C ≥ 100 mg/dL and triglycerides 150-500 mg/dL...
March 14, 2024: European Journal of Preventive Cardiology